Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 3Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Plasma cell 1Breast 1

Conditions

Leukemia, Myeloid, Acute 51Multiple Myeloma 25Myelodysplastic Syndromes 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 23Lymphoma 22Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 21Melanoma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Neoplasms 13Hodgkin Disease 13Neoplasm Metastasis 12Recurrence 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Skin Neoplasms 8Neoplasms, Plasma Cell 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 8Kidney Neoplasms 8Ovarian Neoplasms 7Myeloproliferative Disorders 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Primary Myelofibrosis 5Anemia, Refractory, with Excess of Blasts 5

Interventions

Paclitaxel 20Carboplatin 16liposomal doxorubicin 10Bevacizumab 10Gemcitabine 8Topotecan 7Taxes 7Cisplatin 7pembrolizumab 6Doxorubicin 5Cyclophosphamide 5Nivolumab 4fludarabine 3Oxaliplatin 3Immunoglobulin G 3Hyperthermic Intraperitoneal Chemotherapy 3Disulfides 3Cytoreduction Surgical Procedures 3trebananib 2talazoparib 2rucaparib 2peginterferon alfa-2b 2olaparib 2fludarabine phosphate 2aldesleukin 2Surgical Procedures, Operative 2STA 9090 2Platinum 2Lenalidomide 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Fallopian Tube Neoplasms × fludarabine × Clear all
NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Gilead Sciences

Phase 1 Terminated
16 enrolled
BreastGynecologicPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01312376 2020-04-24

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Terminated
18 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00652899 2017-12-28

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
14 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡